Clinical Trial of Elemene Injection/Elemene Oral Emulusion in Combination With the Best Supportive Treatment in the Treatment of Advanced Primary Liver Cancer
Clinical Trial of Elemene Injection/Elemene Oral Emulusion in Combination With the Best Supportive Treatment in the Treatment of Advanced Primary Liver Cancer
Advanced Primary Liver Cancer
DRUG: Elemene Injection/Elemene Oral Emulusion
DCR and/or 6-months survival rate, Disease control rate.The proportion of patients who had a best response rating of complete response, partial response, or stable disease/, 6 months
ORR, Objective response rate.The proportion of patients who had a best response rating of complete response and partial response., 1year|PFS, Progression-free survival.The time of patients from randomization to death caused by the progression of the tumor or any cause, 1 year|OS, Overrall survival.The time of patient from randomization to death caused by any cause, 3 year|QLQ, Quality of Life Questionnaire Core 30, 3 year|the rate of incidence of adverse events, NCI CTC AE 4.03, 3 year
Patients with advanced primary liver cancer will be enrolled in the trial , then the patients will be treated with the Elemene Injection/Elemene Oral Emulusion in Combination with the best supportive treatment .The purpose of the study is to evaluate the effect and safety of the Elemene Injection/Elemene Oral Emulusion in Combination with the best supportive treatment in the treatment of advanced primary liver cancer